| Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates AO Hoff, BB Toth, K Altundag, MM Johnson, CL Warneke, M Hu, A Nooka, ... Journal of Bone and Mineral Research 23 (6), 826-836, 2008 | 829 | 2008 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Rituximab-related viral infections in lymphoma patients S Aksoy, H Harputluoglu, S Kilickap, DS Dede, O Dizdar, K Altundag, ... Leukemia & lymphoma 48 (7), 1307-1312, 2007 | 288 | 2007 |
| Association between common risk factors and molecular subtypes in breast cancer patients FP Turkoz, M Solak, I Petekkaya, O Keskin, N Kertmen, F Sarici, Z Arik, ... The Breast 22 (3), 344-350, 2013 | 229 | 2013 |
| Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis K Altundag, ML Bondy, NQ Mirza, SW Kau, K Broglio, GN Hortobagyi, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 207 | 2007 |
| Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy AO Hoff, BB Toth, K Altundag, V Guarneri, A Adamus, AK Nooka, ... Journal of Clinical Oncology 24 (18_suppl), 8528-8528, 2006 | 182 | 2006 |
| Aromatase inhibitors in breast cancer: an overview K Altundag, NK Ibrahim The Oncologist 11 (6), 553-562, 2006 | 170 | 2006 |
| Manipulating the chemokine‐chemokine receptor network to treat cancer PA Ruffini, P Morandi, N Cabioglu, K Altundag, M Cristofanilli Cancer 109 (12), 2392-2404, 2007 | 165 | 2007 |
| First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients IE Smith, JY Pierga, L Biganzoli, H Cortés-Funes, C Thomssen, X Pivot Ann Oncol 22 (3), 595-602, 2011 | 135 | 2011 |
| Do yoga and aerobic exercise training have impact on functional capacity, fatigue, peripheral muscle strength, and quality of life in breast cancer survivors? N Vardar Yağlı, G Şener, H Arıkan, M Sağlam, D İnal İnce, S Savcı, ... Integrative cancer therapies 14 (2), 125-132, 2015 | 133 | 2015 |
| From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures MC Boruban, K Altundag, GS Kilic, J Blankstein European Journal of Cancer Prevention 17 (2), 133-138, 2008 | 131 | 2008 |
| Cardiotoxicity of novel HER2-targeted therapies MAN Sendur, S Aksoy, K Altundag Current medical research and opinion 29 (8), 1015-1024, 2013 | 113 | 2013 |
| Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer B Boyraz, MAN Sendur, S Aksoy, T Babacan, EC Roach, ... Current medical research and opinion 29 (4), 405-414, 2013 | 111 | 2013 |
| Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with … E Sari, G Guler, M Hayran, I Gullu, K Altundag, Y Ozisik Medical Oncology 28, 57-63, 2011 | 108 | 2011 |
| Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension M Dincer, K Altundag Annals of Pharmacotherapy 40 (12), 2278-2279, 2006 | 99 | 2006 |
| Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature C Arslan, E Sari, S Aksoy, K Altundag Expert opinion on therapeutic targets 15 (1), 21-30, 2011 | 97 | 2011 |
| Breast cancer subtypes and outcomes of central nervous system metastases UY Arslan, B Oksuzoglu, S Aksoy, H Harputluoglu, I Turker, Y Ozisik, ... The Breast 20 (6), 562-567, 2011 | 93 | 2011 |
| EGFR expression and gene copy number in triple-negative breast carcinoma B Gumuskaya, M Alper, S Hucumenoglu, K Altundag, A Uner, G Guler Cancer genetics and cytogenetics 203 (2), 222-229, 2010 | 92 | 2010 |
| Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor–related arthralgia O Dizdar, L Özçakar, FÜ Malas, H Harputluoglu, N Bulut, S Aksoy, ... Journal of Clinical Oncology 27 (30), 4955-4960, 2009 | 90 | 2009 |
| Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients F Karatas, GU Erdem, S Sahin, A Aytekin, D Yuce, AR Sever, T Babacan, ... The Breast 32, 237-244, 2017 | 87 | 2017 |
